One of the hottest issues in medtech reimbursement is whether there is a  need for an expedited reimbursement program following the repeal of  MCIT. In this episode of the Market Pathways podcast, former CMS  Administrator and FDA Commissioner Mark McLellan weighs in on this and  other reimbursement and regulatory concerns facing the device industry.  

#medtech #MedicalDevices #FDA #CMS #MCIT

View the latest issue of Market Pathways: https://bit.ly/3M4gsLc

View more podcast episodes: https://bit.ly/3vgFTlT

About Market Pathways

Your premium guide to global medical device regulation, reimbursement   and  policy. Market Pathways delivers incomparable intelligence   exploring the  people, challenges, and opportunities impacting the   global medtech  regulatory and reimbursement community. View the latest   issue of Market  Pathways on MyStrategist.com